Ultime notizie per Sino Golf Holdings (OTC:SGFHF) Azioni

Sino Golf Holdings Ltd is an investment holding company. Along with its subsidiaries, it is engaged in manufacturing and trading golf equipment, golf bags, and accessories, and developing integrated resorts in the Commonwealth of the Northern Mariana Islands. The group's reportable segments are Golf equipment, Golf bags, and Hospitality. The majority of its revenue is generated from the Golf equipment segment, which is involved in manufacturing and selling golf equipment and related components and parts. Geographically, the group generates maximum revenue from its customers in Japan, followed by North America, Europe, Asia (excluding Japan), and other regions.

SINO GOLF HOLDINGS LTD by Sino Golf Holdings Ltd.

Sino Golf Holdings Ltd

WIIM

KARO

Karooooo shares are trading lower after the company announced the pricing of an $75 million underwritten public offering of 1.50 million ordinary shares held by CEO Isaias Jose Calisto at $50 per share.

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares closed lower on Wednesday as investors continued to digest announcements from this week's <a href="https://www.benzinga.com/topic/wwdc">Worldwide Developers Conference.</a>
The much-anticipated event showcased updates across Apple's operating systems, including a new design language called "Liquid Glass," but left some analysts and investors underwhelmed by its advancements in artificial intelligence.
With the recent buzz around Apple, some investors may be eyeing potential gains from the company's dividends too. As of now, Apple offers an annual dividend yield of 0.52%, which is a quarterly dividend amount of 26 cents per share ($1.04 a year).
To figure out how to earn $500 monthly from Apple, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Apple $1.04 dividend: $6,000 / 1.04 = 5,769 shares.
So, an investor would need to own approximately $1,146,762 worth of Apple, or 5,769 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.04 = 1,154 shares, or $229,392 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
AAPL Price Action: Shares of Apple fell by 1.9% to close at $198.78 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a></li>
</ul>
Photo: Akhenaton Images/Shutterstock

Earnings

Long Ideas

News

Dividends

Markets

Trading Ideas

AAPL

How To Earn $500 A Month From Apple Stock

IonQ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NASDAQ">IONQ</a>) is solidifying its stronghold in the quantum computing space as a recent sector endorsement by Jensen Huang, partnership with Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), and the <a href="https://www.benzinga.com/m-a/25/06/45832398/ionq-buys-oxford-ionics-in-1-075-billion-deal-to-supercharge-quantum-tech">acquisition of Oxford Ionics</a> have drawn investor attention to the company.
What Happened: Its recent definitive agreement to acquire U.K.-based Oxford Ionics for $1.075 billion will &#8220;meaningfully accelerate IonQ&#8217;s technology roadmap,&#8221; said Needham.
This strategic move propels IonQ towards ambitious targets: a 256 physical qubit system by 2026, 10,000 physical qubits by 2027, and a staggering 2 million physical qubits by 2030, all while achieving increasingly higher logical accuracy.
Needham highlights that these targets will be achieved as IonQ leverages Oxford&#8217;s ion-trap technology and uses its own control software, networking stack, and manufacturing capabilities
Needham &amp; Company has reiterated its &#8220;Buy&#8221; rating on IonQ, maintaining a $50 price target in a note dated June 11.
This comes as Nvidia CEO Huang turned back on his <a href="https://www.benzinga.com/markets/equities/25/01/42867168/nvidias-jensen-huang-said-something-that-has-all-quantum-computing-stocks-tumbling-qubt-and-rgti-down-13-ionq-down-11">January statement</a>, and said quantum computing is reaching a pivotal &#8220;<a href="https://www.benzinga.com/markets/tech/25/06/45885805/nvidias-jensen-huang-sparks-quantum-stock-frenzy">inflection point</a>,&#8221; during his keynote speech at a company event being held jointly with the VivaTech 2025 conference in Paris. 
He also added that quantum computing is poised to &#8220;solve some interesting problems&#8221; globally in the coming years.
See Also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45900891/mark-cuban-backs-ro-khannas-12-trillion-progressive-deficit-reduction-plan-targetin">Mark Cuban Backs Ro Khanna&#8217;s $12 Trillion &#8216;Progressive Deficit Reduction Plan,&#8217; Targeting Medicare Fraud And Military Spending</a>
Why It Matters: The path to practical quantum advantage increasingly involves hybrid quantum-classical computing, and IonQ has demonstrated its leadership in this domain after a partnership with Nvidia.
It is already working on <a href="https://ionq.com/news/ionq-to-advance-hybrid-quantum-computing-with-new-chemistry-application-and">hybrid computing</a>, leveraging the NVIDIA CUDA-Q platform alongside its IonQ Forte hardware. This collaboration illustrates the seamless integration of quantum processing units (QPUs) with Nvidia&#8217;s accelerated computing capabilities. 
Further solidifying this synergy, IonQ, in partnership with AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Amazon.com Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Web Services (AWS), and Nvidia, recently achieved a remarkable 20 times speedup in a <a href="https://ionq.com/news/ionq-speeds-quantum-accelerated-drug-development-application-with#:~:text=COLLEGE%20PARK%2C%20MD%20%2D%20June%209,quantum%2Daccelerated%20computational%20chemistry%20workflow">critical drug development workflow</a>. 
Price Action: Shares of IonQ ended 0.10% lower on Wednesday, and they were down 1.81% in premarket on Friday. It has fallen 7.89% on a year-to-date basis and surged 399.37% over a year.
About seven analysts covering IonQ are <a href="https://www.benzinga.com/quote/IONQ/analyst-ratings">tracked by Benzinga</a>. They have a consensus target price of $40 apiece, with a ‘hold' rating. The targets range from $30 to $50, and the recent ratings by Needham, Benchmark, and Morgan Stanley imply a 10.91% upside for the stock.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/IONQ/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="384" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12075115/ANR-IONQ-1024x384.png" alt="" class="wp-image-947500" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12075115/ANR-IONQ-1024x384.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12075115/ANR-IONQ-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12075115/ANR-IONQ-768x288.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12075115/ANR-IONQ.png 1282w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Benzinga Edge Stock Rankings shows that IonQ had a stronger price trend over the short, medium, and long term. Its momentum ranking was solid; however, its value ranking was poor at the 3.20th percentile. The details of other metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="148" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12074600/IONQ-EDGE-1024x148.png" alt="" class="wp-image-947495" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12074600/IONQ-EDGE-1024x148.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12074600/IONQ-EDGE-300x43.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12074600/IONQ-EDGE-768x111.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12074600/IONQ-EDGE.png 1044w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Thursday. The SPY was down 0.51% at $598.30, while the QQQ declined 0.54% to $529.51, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45899298/automotive-and-apparel-companies-absorbed-tariff-costs-amid-better-than-expected-may-cpi-print-but-dont-expect-that-to-continue-says-expert">Automotive And Apparel Companies &#8216;Absorbed Tariff Costs&#8217; Amid Better Than Expected May CPI Print: &#8216;But Don&#8217;t Expect That To Continue,&#8217; Says Expert</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

AMZN

IONQ

NVDA

Jensen Huang's Quantum Support Boosts IonQ's Growth Plans: Nvidia Partnership, Oxford Ionics Deal Lead Needham To Reiterate 'Buy'

Jefferies analyst Julien Dumoulin-Smith upgrades TransAlta (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TA#TSX">TA</a>) from Hold to Buy and raises the price target from C$12 to C$20.

Upgrades

Price Target

Analyst Ratings

TSX:TA

Jefferies Upgrades TransAlta to Buy, Raises Price Target to C$20

TIXT

TELUS shares are trading higher after the company announced it proposed the acquisition of TELUS Digital to accelerate AI and SaaS transformation across core business sectors.

CACI

CACI International Awarded 7-Yr Task Order With Estimated Ceiling Of $437M For Support To U.S. Africa Command's Mission

<ul>
<li>LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke</li>
<li>Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use averages $39,000 per event</li>
<li>Tecarfarin, with its novel metabolic pathway, potentially may offer an alternative to warfarin in this vulnerable population</li>
</ul>
Cadrenal Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>), a biopharmaceutical company developing novel therapeutics for patients with cardiovascular disease, today announced new findings from third-party research on the economic and medical burdens faced by advanced heart failure patients with left ventricular assist devices (LVAD) requiring chronic anticoagulation.
The research recently conducted by Guidehouse, an AI-led professional services firm delivering advisory, technology, and managed services to the commercial and government sectors, underscores the significant clinical and economic burden for LVAD patients who require chronic oral anticoagulation. Key findings include:
<ul>
<li>Major bleeds remain a primary cost driver, with average hospitalization costs (per event) of $54,100 for intracranial hemorrhage, $26,900 for gastrointestinal bleeds, and $36,600 for other major bleeds.</li>
</ul>
Guidehouse's analysis also identified tecarfarin – a novel, Phase 3–ready oral anticoagulant being developed by Cadrenal – as a potential alternative to warfarin to address the current unmet need in this patient population. Tecarfarin is designed to provide more consistent anticoagulation control by avoiding the multiple metabolic pathways associated with warfarin. Its unique metabolism via a single enzyme (CES2) may reduce the risk of drug interactions, dietary complications, and adverse bleeding or thrombotic events.

Biotech

General

CVKD

Cadrenal Therapeutics Highlights Tecarfarin As Safer Anticoagulant Alternative For High-Risk LVAD Patients

PPTA

Perpetua Resources shares are trading lower after the company announced a $300 million bought financing deal and a $100 million private placement.

ZENA

ZenaTech's ZenaDrone To Filed Patent And Accelerate Deployment Of Counter-UAS Technology

Today Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and DICK'S Sporting Goods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) announced a new partnership that brings the retailer's broad selection of sporting goods, athletic apparel, footwear, team sports gear, golf equipment, fan merchandise and more to the Uber Eats platform. With over 800 DICK'S Sporting Goods and Golf Galaxy locations across the country available on Uber Eats beginning this week, customers can enjoy convenient, on-demand or scheduled delivery of the retailer's hottest products—all at the tap of a button.
Starting today, athletes, fans, and outdoor enthusiasts alike can browse and purchase a wide range of products—from fitness equipment and cleats to golf balls and team jerseys—directly through the Uber Eats app. To celebrate the launch, new and existing Uber Eats users can take advantage of up to 30% off of select athletic essentials, sport accessories and outdoor gear†. As always, Uber One members enjoy added perks, including $0 Delivery Fees on eligible orders††.

UBER

Uber Eats Partners With DICK'S Sporting Goods To Offer On-Demand Delivery Of Sporting Goods Nationwide

– Potential to Address a Broad Range of Complement-Mediated Diseases with Initial Focus on Immune Platelet Transfusion Refractoriness and Refractory Antiphospholipid Syndrome –
– Data Readouts Expected from Cohort 1 in 3Q 2025 and Cohort 2 in 4Q 2025 –
Rallybio Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, the Company's innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor.
Additionally, Rallybio announced that the initial indication focus for RLYB116 will be on two hematologic conditions with significant unmet need: immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). Patients suffering from these potentially life-threatening conditions have no approved or effective therapeutic options.

RLYB

Rallybio Initiates Dosing In Phase 1 Confirmatory PK/PD Study Evaluating RLYB116, Subcutaneously Injected C5 Inhibitor

Equinox Gold shares are trading lower. The company updated its FY25 guidance.

Asset Sales

THRD

Third Harmonic Bio Announces Stockholder Approval Of Liquidation And Dissolution Plan With Initial Distribution Expected In The Range Of $5.30-$5.35; Co. Initiates Sale Process Of THB335

BeOne Medicines shares are trading higher after the company announced that the FDA approved a new tablet formulation of BRUKINSA for all five approved indications.

enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.49) by 4.08 percent. This is a 34.21 percent decrease over losses of $(0.38) per share from the same period last year.

Earnings Misses

ENGN

enGene Holdings Q2 EPS $(0.51) Misses $(0.49) Estimate

Uxin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) sees Q2 Total revenues to range between RMB 630M and RMB 660M. &nbsp;

Guidance

UXIN

Uxin Sees Q2 Total revenues to range between RMB 630M and RMB 660M.

Stock Split

Jianzhi Education To Implement ADS Ratio Change From 1 ADS Representing 6 Ordinary Shares To  ADS Representing 60 Shares

Highlights Board's proactive measures to increase long-term stockholder value and record of effective oversight
Urges stockholders to vote "FOR" Oportun's two highly qualified nominees – CEO Raul Vazquez and Carlos Minetti – on the GREEN proxy card
SAN CARLOS, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- Oportun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>), a mission-driven financial services company, today issued a <a href="https://www.globenewswire.com/Tracker?data=V0jrSm4zoi3E6Szw-O51va69NIDse_FY0wja9KEBqusZ-SLNRJWuToIYodzhYjatz5z05ekZrbP61gohTxAir212gOG8na1IeJH6ykel__fb-JFaebqyvIMF3LP2ZQFp8sGRdd3kH-WMWlDvueIkAZUbhfA1I2VaMit_Q_Wq_8cB-6kTKUQ93OWlZ66u90YWX8EV350qgyrwbnWu2vPLv8wrSv40TET5B31nlm7_oRqk-jN1u14qPVeCowlKErcZ">letter to stockholders</a> from Lead Independent Director Neil Williams detailing the actions that Oportun's Board of Directors has taken to drive improved financial performance and reposition the Company for future success.
After nearly eight years of dedicated service to Oportun's Board, Mr. Williams plans to retire at the Company's upcoming 2025 Annual Meeting of Stockholders. In his letter urging shareholders to vote in favor of Oportun's skilled and experienced nominees, Mr. Williams highlights:
<ul>
<li>In response to the changing economic environment, Oportun announced a detailed plan to reduce expenses and streamline operations in February 2023.</li>
<li>The announcement of that plan took place nearly two months before the Company was aware that Findell Capital Management was a stockholder. Over the next two years, Oportun:
<ul>
<li>Executed multiple reductions in force; eliminated expenses across the organization; initiated a strategic review process for the Company's credit card portfolio that eventually resulted in its sale; and discontinued several non-core businesses.</li>
</ul>
</li>
<li>Oportun has driven $240 million in cost savings since mid-2022, and over the last two quarters returned to GAAP profitability.</li>
<li>Oportun's highly engaged and qualified Board possesses the right mix of skills and experience to continue driving Oportun's strong momentum. The expertise of the Company's nominees, CEO Raul Vazquez and Carlos Minetti, aligns with the needs of the business and provides a strong foundation to guide Oportun moving forward.</li>
</ul>

Management

OPRT

Oportun Urges Shareholders To Support Board Nominees Amid $240M Cost Savings Since Mid-2022 And Returning To Profitability

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) with a Buy and maintains $12 price target.

SNTI

Chardan Capital Maintains Buy on Senti Biosciences, Maintains $12 Price Target

<ul>
<li>Key complex product approval in the Affordable Medicines segment this year</li>
<li>Commercial launch planned for third quarter of 2025</li>
</ul>
BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte&#xAE;. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third quarter of 2025.
Prednisolone acetate ophthalmic suspension, USP 1% is a sterile, topical anti-inflammatory agent for ophthalmic use and is indicated for treating steroid-responsive ocular inflammation.
According to IQVIA&#xAE; U.S. annual sales for prednisolone acetate ophthalmic suspension for the 12 months ended April 2025 were approximately $201 million.

AMRX

Amneal Pharma Announces FDA Approval For Prednisolone Acetate Ophthalmic Suspension; Product Launch Planned For Q3 2025

Sino Golf Holdings

Comments

Sino Golf Holdings

Notizie

Ultime notizie per Sino Golf Holdings (OTC:SGFHF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO